Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company that is developing innovative precision medicine for debilitating musculoskeletal diseases. The Company is leveraging its knowledge and expertise in muscle biology, biophysics and small molecules to create a pipeline of candidates that address large unmet...
Perficient, Inc. (NASDAQ: PRFT) is a Digital Consultancy Services and solutions provider for a plethora of industries such as Automotive, Energy and Utility Services, Healthcare, Life Sciences, Financial Services and Manufacturing to name a few. The Company has shown great resilience against the pandemic and...
VirnetX Holding (NYSE: VHC), a Company developing leading-edge solutions and technology for internet security, announced the receipt of $502.8 million and the grant of its motion for pre-trial and post-trial interest, supplemental damages, costs, and ongoing royalty of a rate set at $0.84 per infringing...
Magenta Therapeutics Inc (NASDAQ: MGTA), a Company pioneering research in stem cell transplant to reset the immune system in order to combat autoimmune, blood cancers and genetic diseases, provided a development update for MGTA-145, a CXCR2 agonist that is intended as a first-line therapy for...
Altimmune Inc (NASDAQ: ALT), a clinical stage biotechnology Company developing immunotherapies for unmet medical needs, announced that the Company has completed designing and synthesis of a novel single-dose, intranasal vaccine to protect against COVID-19, developed using its proprietary intranasal vaccine technology. [caption id="attachment_20787" align="aligncenter" width="271"] Image...
Axcella Health (NASDAQ: AXLA), a biotechnology Company focussed on leveraging the power of Endogenous Metabolic Modulators, announced the issuance of a third EMM-related patent covering an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). The patent broadens...
Foamix and Menlo Therapeutics have signed a definitive merger agreement to form a biopharmaceutical Company focused on dermatological conditions. The combined entity will have a robust portfolio of diversified candidates, including an approved product and three late-stage clinical candidates. Foamix’s AMZEEQ™ (minocycline) topical foam, 4%, recently...
Obseva (NASDAQ: OBSV), a biopharmaceutical Company focused on women’s reproductive health announced the discontinuation of nolasiban (OBE001), an oral oxytocin receptor antagonist intended for women undergoing embryo transfer (ET) following in-vitro fertilization (IVF). The candidate, though well-tolerated, failed to meet the primary endpoint of an increase...
ParcelPal Technologies (CNSX: PKG) (OTCPK: PTNYF), a Canadian on-demand local delivery service provider, announced the completion of a major milestone of delivering over 2,500,000 packages to date. The company is disrupting the local delivery business by using cutting edge technology, that connects customers and businesses,...
